Use of pharmacogenetics to guide warfarin therapy.

Journal Article (Journal Article)

The Human Genome Project heralds new opportunities for pharmacogenetics, the use of genetics to individualize the application of pharmaceuticals in the practice of medicine (1-3). Single nucleotide polymorphisms (SNPs) and other genetic variants in genes responsible for absorption, metabolism and excretion have been associated with alterations in drug disposition or effect. Warfarin is a potential target for pharmacogenetics-based dosing because of its wide use, variability in individual response, high prevalence of genetic variants and severity of adverse drug reactions (4). The genotype assays for genetic variants relevant to warfarin are widely used and are being developed for commercial use (5), making the promise of a pharmacogenetics-based approach a near reality.

Full Text

Duke Authors

Cited Authors

  • Voora, D; McLeod, HL; Eby, C; Gage, BF

Published Date

  • March 2004

Published In

Volume / Issue

  • 40 / 3

Start / End Page

  • 247 - 257

PubMed ID

  • 15148533

International Standard Serial Number (ISSN)

  • 1699-3993

Digital Object Identifier (DOI)

  • 10.1358/dot.2004.40.3.820088


  • eng

Conference Location

  • Spain